Halozyme Therapeutics, Inc.

LSE:0J2O Stock Report

Market Cap: US$6.0b

Halozyme Therapeutics Valuation

Is 0J2O undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0J2O when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0J2O ($47.44) is trading below our estimate of fair value ($169.27)

Significantly Below Fair Value: 0J2O is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0J2O?

Key metric: As 0J2O is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0J2O. This is calculated by dividing 0J2O's market cap by their current earnings.
What is 0J2O's PE Ratio?
PE Ratio15.4x
EarningsUS$392.47m
Market CapUS$6.05b

Price to Earnings Ratio vs Peers

How does 0J2O's PE Ratio compare to its peers?

The above table shows the PE ratio for 0J2O vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average48.2x
GNS Genus
126.7x31.5%UK£1.0b
BVXP Bioventix
20.6xn/aUK£167.0m
HIK Hikma Pharmaceuticals
19.4x12.2%UK£4.4b
002252 Shanghai RAAS Blood Products
26.1x18.2%CN¥47.7b
0J2O Halozyme Therapeutics
15.4x21.1%US$6.0b

Price-To-Earnings vs Peers: 0J2O is good value based on its Price-To-Earnings Ratio (15.4x) compared to the peer average (48.2x).

Price to Earnings Ratio vs Industry

How does 0J2O's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0J2O 15.4xIndustry Avg. 26.9xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0J2O is good value based on its Price-To-Earnings Ratio (15.4x) compared to the European Biotechs industry average (26.9x).

Price to Earnings Ratio vs Fair Ratio

What is 0J2O's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0J2O PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.4x
Fair PE Ratio28.7x

Price-To-Earnings vs Fair Ratio: 0J2O is good value based on its Price-To-Earnings Ratio (15.4x) compared to the estimated Fair Price-To-Earnings Ratio (28.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0J2O forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$47.44
US$64.13
+35.2%
12.6%US$75.00US$52.00n/a8
Dec ’25US$48.27
US$62.44
+29.4%
14.2%US$75.00US$50.00n/a9
Nov ’25US$57.13
US$62.50
+9.4%
13.7%US$75.00US$50.00n/a10
Oct ’25US$56.49
US$61.10
+8.2%
13.5%US$75.00US$48.00n/a10
Sep ’25US$63.47
US$59.10
-6.9%
12.1%US$72.00US$48.00n/a10
Aug ’25US$54.72
US$57.90
+5.8%
11.3%US$72.00US$49.00n/a10
Jul ’25US$51.57
US$57.40
+11.3%
12.8%US$72.00US$44.00n/a10
Jun ’25US$43.91
US$51.30
+16.8%
15.6%US$71.00US$41.00n/a10
May ’25US$39.41
US$50.50
+28.1%
17.1%US$72.00US$39.00n/a11
Apr ’25US$40.86
US$50.70
+24.1%
17.8%US$72.00US$39.00n/a10
Mar ’25US$41.48
US$48.64
+17.3%
22.2%US$72.00US$28.00n/a11
Feb ’25US$33.55
US$47.50
+41.6%
23.9%US$72.00US$28.00n/a10
Jan ’25US$36.86
US$50.30
+36.5%
22.4%US$72.00US$28.00n/a10
Dec ’24US$39.66
US$51.27
+29.3%
21.5%US$72.00US$28.00US$48.2711
Nov ’24US$33.48
US$51.27
+53.1%
21.6%US$72.00US$28.00US$57.1311
Oct ’24US$38.25
US$51.80
+35.4%
21.9%US$72.00US$28.00US$56.4910
Sep ’24US$42.77
US$51.80
+21.1%
21.9%US$72.00US$28.00US$63.4710
Aug ’24US$42.99
US$50.60
+17.7%
24.1%US$72.00US$26.00US$54.7210
Jul ’24US$35.65
US$48.56
+36.2%
23.2%US$66.00US$26.00US$51.579
Jun ’24n/a
US$49.60
0%
21.3%US$66.00US$26.00US$43.9110
May ’24US$31.87
US$52.40
+64.4%
23.1%US$68.00US$26.00US$39.4110
Apr ’24US$36.76
US$52.70
+43.4%
23.1%US$68.00US$26.00US$40.8610
Mar ’24US$48.28
US$56.22
+16.4%
22.6%US$68.00US$26.00US$41.489
Feb ’24US$51.84
US$56.22
+8.4%
22.0%US$68.00US$26.00US$33.559
Jan ’24US$56.15
US$56.00
-0.3%
23.7%US$68.00US$23.00US$36.869
Dec ’23US$57.00
US$53.22
-6.6%
22.5%US$65.00US$23.00US$39.669

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 14:52
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Halozyme Therapeutics, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
James BirchenoughBarclays
Robert WassermanBenchmark Company